Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

155.35
+0.77000.50%
Pre-market: 155.410.0550+0.04%09:18 EDT
Volume:5.82M
Turnover:902.13M
Market Cap:373.78B
PE:17.29
High:155.81
Open:155.50
Low:153.82
Close:154.58
Loading ...
OverviewCompanyNewsFilings

Top Midday Stories: Boeing Wins Multibillion Dollar Contract to Build Fighter Jet; FedEx Shares Fall on Earnings Miss, Downbeat Guidance

MT Newswires Live
·
22 Mar

J&J is latest company trying to get on Trump's good side with big U.S. investment

Investing.com
·
21 Mar

Johnson & Johnson Boosts Planned US Investment to More Than $55 Billion

MT Newswires
·
21 Mar

Stocks to Watch Friday: J&J, Nike, FedEx, Micron -- WSJ

Dow Jones
·
21 Mar

FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease

Benzinga
·
21 Mar

Johnson & Johnson to Invest Over $55 Billion in US Over Next Four Years

MT Newswires Live
·
21 Mar

Johnson & Johnson - Investment Represents 25% Increase Compared to Previous Four Years

THOMSON REUTERS
·
21 Mar

J&J: North Carolina Facility Create a $3 Bln Impact Across State in First 10 Years of Operations

THOMSON REUTERS
·
21 Mar

Johnson & Johnson Increases U.S. Investment to More Than $55 Billion Over the Next Four Years

THOMSON REUTERS
·
21 Mar

J&J: Total Company U.S. Economic Impact Estimated to Be More Than $100 Bln per Year

THOMSON REUTERS
·
21 Mar

J&J: Includes Four Planned New Manufacturing Facilities, With Ground-Breaking Today in North Carolina on $2 Bln+ Facility

THOMSON REUTERS
·
21 Mar

Johnson & Johnson - North Carolina Facility to Support 5,000 Jobs During Construction, Create 500 Positions

THOMSON REUTERS
·
21 Mar

Johnson & Johnson's Tremfya Receives US FDA Approval for Crohn's Disease

MT Newswires Live
·
21 Mar

FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease

TIPRANKS
·
21 Mar

BRIEF-US FDA Approves TREMFYA® (Guselkumab), The First And Only IL-23 Inhibitor Offering Both Subcutaneous And Intravenous Induction Options, For Adult Patients With Moderately To Severely Active Crohn's Disease

Reuters
·
21 Mar

U.S. FDA Approves Tremfya® (Guselkumab), the First and Only Il-23 Inhibitor Offering Both Subcutaneous and Intravenous Induction Options, for Adult Patients With Moderately to Severely Active Crohn's Disease

THOMSON REUTERS
·
21 Mar

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference

GlobeNewswire
·
21 Mar

VGS ETF: The case for geographical diversification

MotleyFool
·
21 Mar

Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib) Significantly Outperforms Standard of Care in First-Line Egfr-Mutated Lung Cancer With Compelling New Data at Elcc 2025

THOMSON REUTERS
·
20 Mar

JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease

Zacks
·
19 Mar
More